Bring decades of experience at the forefront of biotechnology, genomics, and medicine.
A pioneer in biotechnology and microbial engineering, Dr. Keasling's lab at UC Berkeley engineered baker's yeast to produce the anti-malarial artemisinic acid. Today, the same technology has shipped millions of low-cost treatments to Africa. Dr. Keasling also founded the DOE Joint BioEnergy Institute (JBEI), an interdisciplinary lab that engineers microbes to produce fuels and materials for the age beyond petroleum. Dr. Keasling's labs have spun-off several companies based on his research. In addition to founder at Demetrix, Dr. Keasling is a professor at UC Berkeley, CEO of JBEI, and Chief Science and Technology Officer for Biosciences at Berkeley National Lab.
With a career spanning HIV biology, cancer, and human genomics, Dr. Haseltine brings decades of experience in medicine and entrepeneurship to Demetrix. Dr. Haseltine was previously professor and founder of two departments at Harvard Medical School, one on HIV/AIDS and one on cancer biology. After fundamental breakthroughs in HIV biology, Dr. Haseltine led Human Genome Sciences, one of the first companies to apply recent discoveries in genetics to treat disease, and founded several other biotechnology companies. In addition to serving as CEO at Demetrix, Dr. Haseltine leads the Haseltine Foundation for Science and the Arts, and ACCESS Health International, both non-profits in health and the humanities.